BR112019007796A2 - construção de vacina e seus usos contra infecções causadas por staphylococcus - Google Patents
construção de vacina e seus usos contra infecções causadas por staphylococcusInfo
- Publication number
- BR112019007796A2 BR112019007796A2 BR112019007796A BR112019007796A BR112019007796A2 BR 112019007796 A2 BR112019007796 A2 BR 112019007796A2 BR 112019007796 A BR112019007796 A BR 112019007796A BR 112019007796 A BR112019007796 A BR 112019007796A BR 112019007796 A2 BR112019007796 A2 BR 112019007796A2
- Authority
- BR
- Brazil
- Prior art keywords
- polypeptide
- seq
- amino acid
- acid sequence
- absent
- Prior art date
Links
- 241000191940 Staphylococcus Species 0.000 title abstract 2
- 238000010276 construction Methods 0.000 title abstract 2
- 208000015181 infectious disease Diseases 0.000 title abstract 2
- 229960005486 vaccine Drugs 0.000 title abstract 2
- 229920001184 polypeptide Polymers 0.000 abstract 22
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 22
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 22
- 150000001413 amino acids Chemical class 0.000 abstract 5
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 4
- 230000004927 fusion Effects 0.000 abstract 2
- 230000002163 immunogen Effects 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 241000344863 Staphylococcus aureus subsp. aureus COL Species 0.000 abstract 1
- 239000011230 binding agent Substances 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 230000002068 genetic effect Effects 0.000 abstract 1
- 230000008018 melting Effects 0.000 abstract 1
- 238000002844 melting Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/085—Staphylococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
- C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Gastroenterology & Hepatology (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Abstract
construção de vacina e seus usos contra infecções causadas por staphylococcus. é fornecida uma construção de fusão da fórmula (i): x-a-ligante-b-z (i) em que: (1) a e b são idênticos ou diferentes e são independentemente: (a) um polipeptídeo compreendendo um polipeptídeo sacol0029 como apresentado em qualquer uma das sequências representadas na fig. 24 (id seq nº.: 5 e 121 a 131), um polipeptídeo sacol0264 (id seq nº: 185), um polipeptídeo sacol0442 como apresentado em qualquer uma das sequências representadas na fig. 22d (id seq nº.: 29 e 82 a 92), um polipeptídeo sacol0718 (id seq nº: 186), um polipeptídeo sacol0720 como apresentado em qualquer uma das sequências representadas nas figs. 23i-j (id seq nº.: 11 e 109 a 120), um polipeptídeo sacol1353 (id seq nº: 187), um polipeptídeo sacol1416 (id seq nº.: 188), um polipeptídeo sacol1611 (id seq nº.: 189), um polipeptídeo sacol1867 como apresentado em qualquer uma das sequências representadas na fig. 25d (id seq nº.: 152 a 164), um polipeptídeo sacol1912 (id seq nº: 43), um polipeptídeo sacol1944 (id seq nº.: 190), um polipeptídeo sacol2144 (id seq nº.: 191), um polipeptídeo sacol2365 (id seq nº.: 192), um polipeptídeo sacol2385 (id seq nº.: 50) ou um polipeptídeo sacol2599 (id seq nº.: 193), com base na nomenclatura genética do genoma de staphylococcus aureus col (sacol) estabelecido na ncbi reference sequence nc_002951.2; (b) um polipeptídeo codificado por um gene de um mesmo operão como um gene que codifica o polipeptídio de (a); (c) um polipeptídio compreendendo um fragmento imunogênico de pelo menos 13 aminoácidos consecutivos de (a) ou (b); (d) um polipeptídeo compreendendo uma sequência de aminoácidos pelo menos 60% globalmente idêntica à sequência do polipeptídeo de qualquer um de (a) a (c); ou (e) um polipeptídio compreendendo uma variante imunogênica compreendendo pelo menos 13 aminoácidos consecutivos de qualquer um de (a) a (c); (2) o ligante é uma sequência de aminoácidos de pelo menos um aminoácido ou está ausente; (3) x está ausente ou é uma sequência de aminoácidos de pelo menos um aminoácido; e (4) z está ausente ou é uma sequência de aminoácidos de pelo menos um aminoácido. também são fornecidas composições e kits que compreendem a fusão e os usos dessas fusões, composições e kits.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662411120P | 2016-10-21 | 2016-10-21 | |
PCT/CA2017/051253 WO2018072031A1 (en) | 2016-10-21 | 2017-10-20 | Vaccine constructs and uses thereof against staphylococcus infections |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112019007796A2 true BR112019007796A2 (pt) | 2019-09-03 |
Family
ID=62018642
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112019007796A BR112019007796A2 (pt) | 2016-10-21 | 2017-10-20 | construção de vacina e seus usos contra infecções causadas por staphylococcus |
Country Status (24)
Country | Link |
---|---|
US (2) | US11324815B2 (pt) |
EP (1) | EP3529260A4 (pt) |
JP (2) | JP7181208B2 (pt) |
KR (1) | KR20190082229A (pt) |
CN (1) | CN109843910A (pt) |
AR (1) | AR109847A1 (pt) |
AU (2) | AU2017346974B2 (pt) |
BR (1) | BR112019007796A2 (pt) |
CA (1) | CA3037070A1 (pt) |
CL (1) | CL2019001048A1 (pt) |
CO (1) | CO2019005169A2 (pt) |
CR (1) | CR20190249A (pt) |
DO (1) | DOP2019000102A (pt) |
IL (1) | IL265869A (pt) |
MX (2) | MX2019004539A (pt) |
MY (1) | MY195369A (pt) |
NZ (1) | NZ751880A (pt) |
PE (1) | PE20191320A1 (pt) |
PH (1) | PH12019500843A1 (pt) |
RU (2) | RU2766354C2 (pt) |
SG (2) | SG10201912431XA (pt) |
TW (1) | TW201819402A (pt) |
UY (1) | UY37448A (pt) |
WO (1) | WO2018072031A1 (pt) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20220185852A1 (en) * | 2020-12-11 | 2022-06-16 | Bayer Animal Health Gmbh | Methods and compositions for improved production of an antigen for use in an s. aureus vaccine |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1288774C (en) | 1985-01-07 | 1991-09-10 | Deborah A. Eppstein | 1,2-dialkoxy-w-trialkylammonium cationic surfactants |
US6228844B1 (en) | 1991-11-12 | 2001-05-08 | Vical Incorporated | Stimulating vascular growth by administration of DNA sequences encoding VEGF |
US7060458B1 (en) | 1997-08-14 | 2006-06-13 | Wyeth | Nucleic acid and amino acid sequences relating to Staphylococcus epidermidis for diagnostics and therapeutics |
US6380370B1 (en) | 1997-08-14 | 2002-04-30 | Genome Therapeutics Corporation | Nucleic acid and amino acid sequences relating to Staphylococcus epidermidis for diagnostics and therapeutics |
US6833134B2 (en) | 2000-06-12 | 2004-12-21 | University Of Saskacthewan | Immunization of dairy cattle with GapC protein against Streptococcus infection |
GB0107661D0 (en) | 2001-03-27 | 2001-05-16 | Chiron Spa | Staphylococcus aureus |
PL229487B1 (pl) | 2002-11-12 | 2018-07-31 | Brigham & Womens Hospital Inc | Kompozycja zawierająca polimer β-1,6-glukozaminy, kompozycja zawierająca przeciwciało, kompozycja farmaceutyczna, sposób wytwarzania wyodrębnionego polisacharydu, sposób identyfikacji obecności deacetylowanej poli-N-acetyloglukozaminy (dPNAG) i/ lub poli-N-acetyloglukozaminy (PNAG), wyodrębniony polisacharyd do zastosowania w leczeniu lub profilaktyce zakażenia, wyodrębniony polisacharyd do zastosowania do wytwarzania przeciwciał, w tym przeciwciał monoklonalnych, wyodrębniony polisacharyd do zastosowania w identyfikacji przeciwciała monoklonalnego |
CN1569893A (zh) | 2003-07-21 | 2005-01-26 | 中国人民解放军军事医学科学院基础医学研究所 | 金葡菌毒力因子调控蛋白的抗原表位及其模拟表位和用途 |
RU2419628C2 (ru) | 2004-09-22 | 2011-05-27 | ГлаксоСмитКлайн Байолоджикалз с.а. | Иммуногенная композиция для применения в вакцинации против стафилококков |
AU2005333603A1 (en) * | 2004-10-21 | 2007-01-04 | Wyeth | Immunogenic compositions of Staphylococcus epidermidis polypeptide antigens |
KR100729954B1 (ko) | 2004-12-01 | 2007-06-20 | 주식회사 엘지생명과학 | Sec1 변이 단백질의 제형 및 그것의 제형화 방법 |
WO2008152447A2 (en) | 2006-10-30 | 2008-12-18 | The University Of Western Ontario | Staphylococcus aureus specific anti-infectives |
BRPI1011856A2 (pt) | 2009-03-23 | 2020-11-03 | Epitopix, Llc | polipeptídeos e composições de imunização contendo polipeptídeos gram-positivos e métodos de uso |
NZ612315A (en) * | 2009-04-14 | 2014-10-31 | Novartis Ag | Compositions for immunising against staphylococcus aureus |
PT2547361T (pt) | 2010-03-17 | 2020-12-07 | Socpra Sciences Et Genie Sec | Componentes de vacina bacteriana de staphylococcus aureus e suas utilizações |
MX340446B (es) | 2011-06-19 | 2016-07-08 | Univ New York | Metodos para tratar y prevenir infecciones por estafilococo dorado y condiciones asociadas. |
-
2017
- 2017-10-20 NZ NZ751880A patent/NZ751880A/en unknown
- 2017-10-20 AR ARP170102922A patent/AR109847A1/es unknown
- 2017-10-20 US US16/337,457 patent/US11324815B2/en active Active
- 2017-10-20 KR KR1020197014191A patent/KR20190082229A/ko active IP Right Grant
- 2017-10-20 WO PCT/CA2017/051253 patent/WO2018072031A1/en unknown
- 2017-10-20 AU AU2017346974A patent/AU2017346974B2/en not_active Ceased
- 2017-10-20 MX MX2019004539A patent/MX2019004539A/es unknown
- 2017-10-20 CA CA3037070A patent/CA3037070A1/en active Pending
- 2017-10-20 RU RU2019115303A patent/RU2766354C2/ru active
- 2017-10-20 SG SG10201912431XA patent/SG10201912431XA/en unknown
- 2017-10-20 JP JP2019542759A patent/JP7181208B2/ja active Active
- 2017-10-20 PE PE2019000844A patent/PE20191320A1/es unknown
- 2017-10-20 CN CN201780064991.1A patent/CN109843910A/zh active Pending
- 2017-10-20 MY MYPI2019002159A patent/MY195369A/en unknown
- 2017-10-20 CR CR20190249A patent/CR20190249A/es unknown
- 2017-10-20 UY UY0001037448A patent/UY37448A/es unknown
- 2017-10-20 TW TW106136089A patent/TW201819402A/zh unknown
- 2017-10-20 EP EP17863203.0A patent/EP3529260A4/en active Pending
- 2017-10-20 BR BR112019007796A patent/BR112019007796A2/pt unknown
- 2017-10-20 RU RU2022100889A patent/RU2022100889A/ru unknown
- 2017-10-20 SG SG11201901483QA patent/SG11201901483QA/en unknown
-
2019
- 2019-04-07 IL IL265869A patent/IL265869A/en unknown
- 2019-04-16 PH PH12019500843A patent/PH12019500843A1/en unknown
- 2019-04-17 CL CL2019001048A patent/CL2019001048A1/es unknown
- 2019-04-17 DO DO2019000102A patent/DOP2019000102A/es unknown
- 2019-04-17 MX MX2023001219A patent/MX2023001219A/es unknown
- 2019-05-21 CO CONC2019/0005169A patent/CO2019005169A2/es unknown
-
2022
- 2022-04-05 US US17/713,683 patent/US20220288183A1/en active Pending
- 2022-06-28 AU AU2022204585A patent/AU2022204585A1/en not_active Abandoned
- 2022-11-16 JP JP2022183528A patent/JP2023025066A/ja not_active Withdrawn
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NI201800121A (es) | Proteínas de fusión gdf15 y usos de estas | |
EA201991440A1 (ru) | ТЕРМОСТАБИЛЬНЫЕ НУКЛЕАЗЫ Cas9 | |
JP2016034981A5 (pt) | ||
MX2020005458A (es) | Variantes de alfa-amilasa y polinucleotidos que codifican las mismas. | |
BR112018008766A2 (pt) | variantes, composições e métodos e utilizações do fator viii reduzido cpg para o tratamento de transtornos hemostásicos | |
BR112018011059A2 (pt) | synp161, um promotor para a expressão específica de genes em fotoreceptores de haste | |
CO2018006947A2 (es) | Novedoso bacteriófago pas-mup-1 de pasteurella multocida y su uso para inhibir la proliferación de pasteurella multocida | |
EP3929285A3 (en) | Methods of reducing odor | |
BR112017013238A2 (pt) | bacteriófago esc-cop-1 de e. coli do tipo f18 produtora de toxina shiga inovador e uso do mesmo para a inibição de proliferação de e. coli do tipo f18 produtora de toxina shiga | |
BR112012033714A2 (pt) | polipeptídeo com atividade de acetil xilano esterase e seus usos. | |
BR112018001121A2 (pt) | vetor recombinante do vírus orf (orfv), célula, composição, uso de um vetor recombinante de orfv, e, molécula de ácido nucleico | |
BR112016011095A2 (pt) | Sequência de endolisina el188 modificada | |
BR112016016103A2 (pt) | Composição de antígenos micobacterianos | |
BR112016011091A2 (pt) | sequência de endolisina kz144 modificada | |
MY187334A (en) | Xylanase | |
BR112019007796A2 (pt) | construção de vacina e seus usos contra infecções causadas por staphylococcus | |
BR112017011621A2 (pt) | gene n?au resistente ao vírus do mosaico do tabaco e métodos de clonagem e suas aplicações | |
BR112017018966A2 (pt) | gene de resistência a míldio em kalanchoe | |
BR112018003580A2 (pt) | molécula de ácido nucléico, método para apresentar um polipeptídeo alvo, proteína recombinante, partícula do tipo viral, composição farmacêutica, polipeptídeo, vetor, célula hospedeira e método para preparar a proteína recombinante | |
WO2014151687A3 (en) | Compositions and methods to treat aids | |
AR125287A1 (es) | Polipéptidos ppo tolerantes a herbicidas inhibidores de ppo y su uso | |
NO20085201L (no) | Rekombinante novirhabdoviruser og deres anvendelse | |
AR107261A1 (es) | Vacuna marcadora de pestivirus | |
BR112018006787A2 (pt) | composições e métodos que compreendem o uso de enzimas alfa-glucanotransferase de exiguobacterium acetylicum e bacillus coagluans | |
BR112021024945A2 (pt) | Variantes de mananase melhoradas |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B25G | Requested change of headquarter approved |
Owner name: SOCPRA SCIENCES ET GENIE S.E.C. (CA) |
|
B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] |